H.C. Wainwright analyst Emily Bodnar downgraded Rapt Therapeutics (RAPT) to Neutral from Buy with a price target of $58, down from $72, after GSK entered into an agreement to acquire all outstanding shares of Rapt for $58 per share in cash. The firm views the acquisition as “logical.”
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT: